Domenico Ribatti
University of Bari
965 Papers
6.1K Citations
Domenico Ribatti is an academic researcher from University of Bari. The author has contributed to research in topics: Angiogenesis & Biology. The author has an hindex of 96, co-authored 913 publications. Previous affiliations of Domenico Ribatti include University of Genoa & National Institutes of Health.
Chat about Author
Papers
The fundamental contribution of William Bate Hardy to shape the concept of mast cell heterogeneity.
TL;DR: The pioneering contribution of William Bate Hardy in shaping the concept of mast cell heterogeneity is acknowledged and it is suggested that different granular basophil cells might express functional specializations.
The embryonic origins of lymphatic vessels: an historical review
TL;DR: The determination of the embryological origin of the lymphatic endothelium has been the most important questions in this field, and more recent evidence has provided support for both hypotheses.
HB-EGF-EGFR Signaling in Bone Marrow Endothelial Cells Mediates Angiogenesis Associated with Multiple Myeloma.
Luigia Rao,Donato Giannico,Patrizia Leone,Antonio Giovanni Solimando,Eugenio Maiorano,Concetta Caporusso,Loren Duda,Roberto Tamma,Rosanna Mallamaci,Nicola Susca,Alessio Buonavoglia,Matteo Claudio Da Via,Domenico Ribatti,Valli De Re,Angelo Vacca,Vito Racanelli +15 more
TL;DR: HB-EGF–EGFR signaling is identified as a potential target of anti-angiogenic therapy, and the clinical investigation of EGFR inhibitors in combination with conventional cytotoxic drugs as a new therapeutic strategy for MM is encouraged.
A historical perspective on milestones in multiple myeloma research.
TL;DR: A historical review of the disease, focused on the main steps, including the definition of Bence Jones proteinuria, the characterization of tumoral plasma cells and serum globulins, and the fundamental contribution of Jan Waldenstrom is presented.
The FGF-2-derived peptide FREG inhibits melanoma growth in vitro and in vivo
Maria Simona Aguzzi,Debora Faraone,Daniela D'Arcangelo,Francesco De Marchis,Gabriele Toietta,Domenico Ribatti,Alberto Parazzoli,Paolo Colombo,Maurizio C. Capogrossi,Antonio Facchiano +9 more
TL;DR: The data indicate that FREG systemic treatment strongly inhibits melanoma metastases development and indicate for the first time that agonists of PDGF-Rα may control melanoma both in vitro and in vivo.